Independent. Not owned by or funded by any pharmaceutical manufacturer.
Evidence-sourced · medically-reviewed where indicated
Delivery formats

Is there a GLP-1 pill?

Evidence-sourced
Written and fact-checked to our published editorial standards.Last updated 2026-09-06. Every clinical claim on this page is sourced to a named primary authority, listed at the foot of the page — see how we research, source, and correct our work.

Direct answer

What you need to know

Evidence strength: Strong

Yes — three of them, and they are the real thing. Rybelsus (oral semaglutide, for type 2 diabetes), Wegovy tablets (oral semaglutide, for weight management), and Foundayo (orforglipron, approved April 2026) are FDA-approved GLP-1 receptor agonists you swallow. All three require a prescription. This is the one non-injectable format that genuinely delivers the medication — patches, gummies and drops do not.

Key takeaways

  • Three approved oral GLP-1 medications exist, and all are prescription-only.
  • They come in two chemically different kinds, which changes how you take them daily.
  • In trials the tablets produced less weight loss than the injections, not more.
  • The cheapest approved GLP-1s are all tablets, and they cost the same: 3 of them — Wegovy, Foundayo and Ozempic — at $149 a month.

Important limitation: The trial figures below come from separate studies with different populations and durations. They are not a head-to-head comparison, and a difference between two trials is weaker evidence than a difference measured within one.

Next action: If injections are the barrier, this is the conversation to have with a prescriber. Our provider directory records who prescribes which products.

Primary sources: DailyMed, U.S. National Library of Medicine, U.S. Food & Drug Administration

General education, not medical advice. We do not publish dosing instructions — follow the label on your own prescription.

The three approved oral GLP-1 medications

Approval status and dosage form are checkable in Drugs@FDA and DailyMed. Self-pay prices are the manufacturer’s published direct-purchase prices, verified 2026-09-06.
ProductMoleculeApproved forSelf-pay from
Wegovy tabletsOral semaglutide (peptide)Chronic weight management$149/mo
Rybelsusalso branded Ozempic tabletsOral semaglutide (peptide)Type 2 diabetes$149/mo
FoundayoOrforglipron (non-peptide small molecule)Chronic weight management$149/mo

The middle row needs explaining, because it is the row most likely to confuse someone comparing prices. Oral semaglutide is sold under two brand names: Rybelsus, and — since a label revision effective 30 January 2026 — Ozempic tablets. One FDA application, NDA213051, carries both names, and it states plainly that the two “are not substitutable on a mg-to-mg basis”: Rybelsus is sold at 3, 7 and 14 mg, the Ozempic tablet from a 1.5 mg tier. So this is still one product on the label and two products on a pharmacy shelf, and only the Ozempic name has a published self-pay price — $149 a month, read 2026-09-06. Nothing published under the Rybelsus name gives a figure, and the strengths differ, so the price cannot simply be read across.

The Foundayo figure is also newer than this page. The table said “not published” for it until 2026-09-06, when we re-read Lilly’s own page and found a self-pay price that had been there for some weeks — recorded in our corrections log.

Every published figure in that column is the same, and that is the fact worth taking from this table: the cheapest FDA-approved GLP-1 medications in the United States are tablets — Wegovy, Foundayo and Ozempic, all at $149 a month. None of them holds that price all the way up. Foundayo is dose-tiered above it, and so is the Wegovy tablet: its 4 mg tier rose to $199 on 31 August 2026, which we confirmed by re-reading NovoCare rather than leaving it standing on the announcement. What each costs at the top of its ladder is set out on the cheapest-routes page.

The two kinds of GLP-1 pill, and why it matters at breakfast

The three products are not chemically equivalent, and the difference is felt daily rather than in a laboratory. Semaglutide is a peptide — a large molecule that the stomach is very good at destroying, which is why the oral versions are formulated to survive the journey and why their labels specify an empty stomach and a waiting period before food, drink, or other medicines.

Orforglipron is a non-peptide small molecule, and that is the whole point of it. It is not a peptide that has to be protected, so it carries no food or water timing restriction. For anyone who has tried to organise a morning around a fasting window, that is a meaningful difference — arguably a larger one than the gap in the trial numbers below.

How the two kinds of GLP-1 tablet differ in daily useTwo timelines. The peptide tablet, oral semaglutide, must be taken on an empty stomach and is followed by a waiting period before eating, drinking, or taking other medicines. The non-peptide tablet, orforglipron, is taken without a timing window. The diagram shows the pattern only and carries no dose figures, waiting times or volumes — those are on the label of your own prescription, and they differ by product.Peptide tabletoral semaglutideTake on an empty stomachWaitThen eat, drink, or take other medicinesNon-peptide tabletorforglipronTake itNo timing window — with or without foodFollow the label on your own prescription: the exact window differs by product.
The peptide tablets ask you to hold a window open before eating. The non-peptide tablet does not. Both are genuine GLP-1 medications.Administration requirements are set by each product's FDA-approved label — see DailyMed, and follow the label on your own prescription. This diagram shows the pattern only and carries no times or volumes.

Do the pills work as well as the injections?

On the published trial results, no — and this is the question the format decision usually turns on, so it is worth being direct about it.

Mean body-weight reduction at the headline dose in each product’s pivotal trial. These are separate trials with different populations and durations, not a head-to-head comparison — each row’s source is listed at the foot of this page.
ProductFormatWeight reductionmean, at the headline doseTrial
Semaglutide (Wegovy)Injection14.9%STEP 1, NEJM 2021 · N=1,961 · 68 weeks
Tirzepatide (Zepbound)Injection22.5%SURMOUNT-1, NEJM 2022 · N=2,539 · 72 weeks
Oral semaglutide (Wegovy pill)Tablet13.6%OASIS 4 · N=307 · 64 weeks
Orforglipron (Foundayo)Tablet12.4%ATTAIN-1 · N>3,100 · 72 weeks

The pill is not a weaker version of the same thing you were going to be prescribed. It is a different product with its own trial, and choosing it is a trade of convenience against the largest published effect.

Two honest caveats about reading that table. These are separate trials, so the differences between rows are softer evidence than a within-trial comparison would be. And a medication you will actually take every week beats one you will abandon — a tablet you tolerate is worth more than an injection you stop. That is a conversation for your prescriber, not a table.

A third, which applies to every row: each figure is a mean, and a mean is the one number in a trial report that describes nobody in particular. The same trials record how many people reached each threshold, which is a more answerable version of the question most people are actually asking.

What a GLP-1 pill costs

At $149 a month, Wegovy tablets bought direct from the manufacturer are the lowest published self-pay price for any FDA-approved medication in this class — below the injection pens of the same drug, and below all but one of the compounded telehealth subscription totals we were able to derive. The full comparison, with membership fees added to medication prices, is in the workings behind that claim.

Two of the three tablets above are semaglutide, and for that molecule the choice of form is the largest single thing you can do about the price — larger than the choice of provider. That case is made in full, provider by provider, in what semaglutide costs in each form it is sold in.

There is a second practical advantage that rarely gets mentioned, because the storage conversation in this category is conducted entirely in terms of pens and cool bags. The tablets are kept at room temperature from start to finish: no refrigeration step at any point, where every injection in the class has one. For anyone who travels, that is often the deciding difference.

“GLP-1 pills” that are not GLP-1 pills

Because a real GLP-1 tablet now exists, the word “pill” has become useful cover for products that contain none. A capsule sold without a prescription is not one of the three products above, whatever the label implies. The same test that works everywhere else in this category works here: if you can buy it without a prescription, it is not a GLP-1 medication. See what supplement products actually contain.

Before you buy anything described as a GLP-1 pill

  • All three approved oral products are prescription-only and dispensed by a pharmacy. There is no legitimate route that skips the prescription.
  • Compounded oral semaglutide is not an FDA-approved product and is not reviewed for identity, purity, or strength.
  • Take the administration instructions from the label on your own prescription, not from a guide online. They differ between these products, which is precisely the point of this page.

Sources

Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.

  1. FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: The approved dosage forms, indications, and administration instructions for each oral product named on this page.
  2. Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Approval status and prescription-only classification, checkable in Drugs@FDA and the Orange Book.
  3. FDA Approves Oral Wegovy: OASIS 4 Trial ResultsApplied Clinical Trials OnlineSupports: The 13.6% mean body-weight reduction reported for Oral semaglutide (Wegovy pill) in OASIS 4 · N=307 · 64 weeks.
  4. Lilly's Oral GLP-1 Orforglipron Demonstrated Meaningful Weight LossEli LillySupports: The 12.4% mean body-weight reduction reported for Orforglipron (Foundayo) in ATTAIN-1 · N>3,100 · 72 weeks.
  5. Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of MedicineSupports: The 14.9% mean body-weight reduction reported for Semaglutide (Wegovy) in STEP 1, NEJM 2021 · N=1,961 · 68 weeks.
  6. Lilly's SURMOUNT-1 Results Published in New England Journal of MedicineEli Lilly (investor release citing NEJM)Supports: The 22.5% mean body-weight reduction reported for Tirzepatide (Zepbound) in SURMOUNT-1, NEJM 2022 · N=2,539 · 72 weeks.
  7. Wegovy cost, coverage and savings informationNovoCare, Novo NordiskSupports: The $149/month self-pay price for Wegovy tablets. Verified 2026-09-06.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.